Skip to content

Suicidal ideation covaries with depressive severity during six-month real-world esketamine treatment in a cohort enriched for borderline personality disorder.

J Affect Disord August 20, 2026 DOI: 10.1016/j.jad.2026.122405 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort Peer reviewed
Population Patients receiving real-world esketamine treatment, enriched for borderline personality disorder
Intervention Esketamine
Duration Six months
Topics Depression Esketamine
Key findings Suicidal ideation covaried with depressive severity over six months of esketamine treatment, suggesting that improvements in suicidal ideation track with improvements in depression in this cohort enriched for borderline personality disorder.

Abstract

Suicidal ideation covaries with depressive severity during six-month real-world esketamine treatment in a cohort enriched for borderline personality disorder.